EMERGENCE OF CANDIDA AURIS IN AUSTRALIA BRINGS NEED FOR SCREENING IN HEALTHCARE FACILITIES

EMBARGOED UNTIL 12:01am Monday 25 May 2020

TWO cases of Candida auris, an emerging, drug-resistant yeast, responsible for hospital outbreaks internationally, were found in one Melbourne hospital ward in 2018, and may be the first instance of transmission of C auris in Australia, according to the authors of a case series published online today by the Medical Journal of Australia.

Associate Professor Leon Worth, an infectious diseases physician at The Royal Melbourne Hospital’s Victorian Healthcare Associated Infection Surveillance Coordinating Centre at the Peter Doherty Institute for Infection and Immunity, and the National Centre for Infections in Cancer and colleagues wrote that C auris was first recognised as a new species of Candida in 2009. Cases have been reported in over 30 countries, including the UK and United Arab Emirates.

“In outbreak settings, bloodstream, urinary tract and deep tissue infections have been reported, in addition to colonisation. The majority of isolates are fluconazole resistant, with variable resistance to amphotericin B and the echinocandin class of antifungal agents. Infection is associated with a crude mortality of 30%.

Worth and colleagues described the case of a 70-year-old man with multiple myeloma who was admitted to Royal Melbourne Hospital after having been hospitalised 10 months earlier in the UK.

“Routine collection of clinical specimens was performed in the setting of an episode of febrile neutropenia. Candida auris was isolated in a urine specimen collected in the presence of an indwelling urinary catheter, without accompanying pyuria,” the authors wrote.

As a result, screening of 73 contacts in the ward was conducted and one other case of C auris was found, in a 38-year-old man with diffuse large B cell lymphoma.

“The organism was detected in a urine specimen collected in the presence of a long-term indwelling urinary catheter. This patient had been admitted to a health care facility in the United Arab Emirates, before direct transfer to our facility about 3 months earlier,” Worth and colleagues wrote.

“Neither patient developed clinical features of urinary tract or disseminated C auris infection and antifungal therapy was not administered.”

The authors wrote that risks for C auris acquisition include admission to a high dependency unit, presence of invasive medical devices, underlying immunocompromise or chronic disease and receipt of antibiotic or antifungal agents.

“One case of C auris invasive disease has previously been reported in Australia, but to our knowledge the two cases identified at our facility represent the first possible transmission of C auris in Australia.”

No further cases have been detected in the hospital where patients from overseas are screened for this and other pathogens.

All MJA media releases are open access and can be found at: https://www.mja.com.au/journal/media

Please remember to credit The MJA.

The Medical Journal of Australia is a publication of the Australian Medical Association.

The statements or opinions that are expressed in the MJA reflect the views of the authors and do not represent the official policy of the AMA or the MJA unless that is so stated.

CONTACTS: Catherine Somerville  
Media and Communications Officer  
Peter Doherty Institute for Infection and Immunity  
Ph: 0422 043 498  
Email: catherine.somerville@unimelb.edu.au